Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications
Open/View files
Date
2016
Author(s)
Publisher
Frontiers Media S.A.
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Bi, Wenya Linda, Michael Zhang, Winona W. Wu, Yu Mei, and Ian F. Dunn. 2016. “Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.” Frontiers in Surgery 3 (1): 40. doi:10.3389/fsurg.2016.00040. http://dx.doi.org/10.3389/fsurg.2016.00040.
Abstract
There has been a recent revolution in our understanding of the genetic factors that drive meningioma, punctuating an equilibrium that has existed since Cushing’s germinal studies nearly a century ago. A growing appreciation that meningiomas share similar biologic features with other malignancies has allowed extrapolation of management strategies and lessons from intra-axial central nervous system neoplasms and systemic cancers to meningiomas. These features include a natural proclivity for invasion, frequent intratumoral heterogeneity, and correlation between biologic profile and clinical behavior. Next-generation sequencing has characterized recurrent somatic mutations in NF2, TRAF7, KLF4, AKT1, SMO, and PIK3CA, which are collectively present in ~80% of sporadic meningiomas. Genomic features of meningioma further associate with tumor location, histologic subtype, and possibly clinical behavior. Such genomic decryption, along with advances in targeted pharmacotherapy, provides a maturing integrated view of meningiomas. We review recent advances in meningioma genomics and probe their potential applications in diagnostic, therapeutic, and prognostic frontiers.
Other Available Sources
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service
Collection
Mapped collections